ERIS Lifesciences' Q4 FY 2025-26 Quarterly Results

Result Summary

• ERIS Lifesciences Ltd reported a 6.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 6.4%.
• Its expenses for the quarter were down by 7.3% QoQ and up 2.4% YoY.
• The net profit increased 156.5% QoQ and increased 172.7% YoY.
• The earnings per share (EPS) of ERIS Lifesciences Ltd stood at 20.57 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

ERIS Lifesciences Ltd is a pharmaceutical company operating in the healthcare sector. The company specializes in developing, manufacturing, and distributing a wide range of pharmaceutical products, primarily focusing on areas such as cardiology, diabetes management, gastroenterology, and orthopedics. As of the latest available data, ERIS Lifesciences is known for its robust product portfolio and market presence in India. The company has been involved in various strategic initiatives to expand its market reach and enhance its product offerings, although specific recent developments within the company are not detailed in the current dataset.

Revenue

For the fourth quarter of fiscal year 2026 (Q4FY26), ERIS Lifesciences Ltd reported a total income of ₹758.79 crores. This represents a decrease of 6.0% compared to the previous quarter (Q3FY26), where the total income was ₹807.47 crores. However, when compared to the same quarter in the previous fiscal year (Q4FY25), there is a growth of 6.4%, as the total income then was ₹713.25 crores. This year-over-year increase suggests a positive growth trajectory in the company’s revenue over the past year, despite the quarter-over-quarter decline.

Profitability

In Q4FY26, the company achieved a profit before tax of ₹160.61 crores, which is an increase of 10.6% from Q3FY26, where the profit before tax was ₹145.23 crores. This also reflects a substantial year-over-year increase of 24.7%, as the profit before tax in Q4FY25 was ₹128.81 crores. The tax component shows a significant change, with a negative value of ₹-119.69 crores in Q4FY26, compared to ₹36.52 crores in Q3FY26 and ₹26.52 crores in Q4FY25. Consequently, the profit after tax for Q4FY26 is ₹279.10 crores, marking a 156.5% increase from the previous quarter and a 172.7% increase from the same quarter last year. The earnings per share (EPS) for Q4FY26 is ₹20.57, which represents an increase of 181.4% QoQ and 198.5% YoY.

Operating Metrics

The total expenses for ERIS Lifesciences Ltd in Q4FY26 amounted to ₹598.18 crores, showing a decrease of 7.3% from Q3FY26, where expenses were ₹645.00 crores. Compared to Q4FY25, the expenses have increased slightly by 2.4% from ₹584.44 crores. The company has demonstrated a decrease in expenses while managing to increase its profit before tax, which is reflected in the improved profitability metrics. The financial data indicates a strategic management of costs and optimization of operations, contributing to the company’s improved financial performance relative to the previous fiscal periods.